Advertisement

Estrogen and Cardiovascular Disease

  • Linda R. Peterson
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)

Abstract

Cardiovascular disease (CVD) is the number one cause of death in women in industrialized countries. Estimates show that a 50-year-old white woman has a 46% probablilty of developing heart disease in her lifetime and a 31% probablilty of dying as a result. Treatment of CVD in women is estimated to cost at least $11 billion dollars per year [1]. However, clinical evidence of coronary artery disease in women is unusual until after menopause. Moreover, premenopausal women who have undergone oopherectomy are at increased risk for atherosclerotic disease when compared with premenopausal women who have not

Keywords

Postmenopausal Woman Oral Contraceptive Premenopausal Woman Obstet Gynecol Estrogen Replacement Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Harlan WR. Cardiovascular disease tare for women: Service utilization, disability, and costs from the National Medical Care Utilization and Expenditure Survey. In Eaker ED, Packard B, Wenger NK, Clarkson TB, Tyroler HA (eds). Coronary Heart Disease in Women. New York: Haymarket Doyma, 1986:55.Google Scholar
  2. 2.
    Parrish HM, Carr CA, Hall DG, King TM. Time interval from castration in premenopausal women to development of excessive coronary atherocslerosis. Am J Obstet Gynecol 99:155, 1967.PubMedGoogle Scholar
  3. 3.
    Green A, Bain C. Epidemiologcal overview of oestrogen replacement and cardiovascular disease. Bailleres Clin Endocrinol Metab 7:95, 1993.CrossRefGoogle Scholar
  4. 4.
    Natchigall LE, Natchigall RH, Natchigall RD, Beckman EM. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54:74, 1979.CrossRefGoogle Scholar
  5. 5.
    Bush T, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, Tyroler HA, Rifkind BM. Estrogen use and all-cause mortality: Preliminary results from the Lipid Research Clinics Program follow-up study. JAMA 249:903, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    Kannel WB, Vokonas PS. Menopause and the risk of cardiovascular disease: The Framingham Study. Ann Intern Med 85:447, 1976.PubMedGoogle Scholar
  7. 7.
    Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster V, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016, 1992.PubMedGoogle Scholar
  8. 8.
    Bush TL. Noncontraceptive estrogen use and risk of cardiovascular disease: An overview and critique of the literature. In Korenman SG (ed). The Menopause. Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Norwell, MA: Serono Symposia, 1990:211.Google Scholar
  9. 9.
    Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 20:47, 1991.PubMedCrossRefGoogle Scholar
  10. 10.
    Manolio TA, Furberg CD, Shemanski L, Psaty BM, O’Leary DH, Tracy RP, Bush TL. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation 88:2163, 1993.PubMedGoogle Scholar
  11. 11.
    Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 150:2557, 1990.PubMedCrossRefGoogle Scholar
  12. 12.
    Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KB. Estrogen replacement therapy after coronary artery bypass surgery: Effect on survival (abstr). J Am Coll Cardiol February (Special issue):7, 1994.Google Scholar
  13. 13.
    Pilote L, Hlatky M. Hormone replacement after menopause: Importance of heart disease in women’s decision making (abstr). J Am Coll Cardiol February (Special issue):51, 1994.Google Scholar
  14. 14.
    American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 117:1038, 1992.Google Scholar
  15. 15.
    Mann JI, Vessey MP, Thorogood M, Doll R. Myocardial infarction in young women with special reference to oral contraceptive practice. Br Med J 2:241, 1975.PubMedGoogle Scholar
  16. 16.
    Mann JI, Inman WHW. Oral contraceptives and death from myocardial infarction. Br Med J 2:245, 1975.PubMedCrossRefGoogle Scholar
  17. 17.
    Mann JI, Inman WHW, Thorogood M. Oral contraceptive use in older women and fatal myocardial infarction. Br Med J 2:445, 1976.PubMedGoogle Scholar
  18. 18.
    Ory H. Association between oral contraceptives and myocardial infarction: A review. JAMA 237:2619, 1977.PubMedCrossRefGoogle Scholar
  19. 19.
    Inman WHW, Vessey MP, Weterholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: A report to rhe Committee on Safety of Drugs. Br Med J 2:203, 1970.PubMedGoogle Scholar
  20. 20.
    Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J 2:199, 1968.PubMedGoogle Scholar
  21. 21.
    Realini JP, Goldzieher JW. Oral contraceptives and cardiovascular disease: A critique of the epidemiologic studies. Am J Obstet Gynecol 152:729, 1985.PubMedGoogle Scholar
  22. 22.
    Stampfer MJ, Wilier WC, Colditz GA, Speizer FE, Hennekens CH. Past use of oral contraceptives and cardiovascular disease: A meta-analysis in the context of the Nurses’ Health Study. Am J Obset Gynecol 163:285, 1990.Google Scholar
  23. 23.
    Sloane D, Shapiro S, Kaufman DW, Rosenberg L, Miettinen OS, Stolley PD. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 305:420, 1981.CrossRefGoogle Scholar
  24. 24.
    Jick H, Dinan B, Rothman KJ. Oral contraceptives and nonfatal myocardial infarction. JAMA 239:1403, 1978.PubMedCrossRefGoogle Scholar
  25. 25.
    Adam SA, Thorogood M. Oral contraception and myocardial infarction revisited: The effects of new preparations and prescribing patterns. Br J Obstet Gynaecol 88:838, 1981.PubMedGoogle Scholar
  26. 26.
    Meade TW, Haines AP, North WR, Chakrabarti R, Howarth DJ, Stirling Y. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram of 30 microgram oestrogen. Lancet 2:948, 1977.PubMedCrossRefGoogle Scholar
  27. 27.
    Samsioe G. Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol 170:1523, 1994.PubMedGoogle Scholar
  28. 28.
    Collaborative Group for the Study of Stroke in Young Women: Oral Contraceptives and stroke in young women: Associated risk factors. JAMA 231:718, 1975.CrossRefGoogle Scholar
  29. 29.
    Collaborative Group for the Study of Stroke in Young Women: Oral contraception and increased risk of cerebral ischemia or thrombosis. N Engl J Med 288:871, 1973.CrossRefGoogle Scholar
  30. 30.
    Peritti DB, Wingerd J. Use of oral contraceptives, cigarette smoking, and risk of subarachnoid hemorrhage. Lancet 2:234, 1978.Google Scholar
  31. 31.
    Inman WH. Oral contraceptives and fatal subarachnoid hemorrhage. Br Med J 2:1468, 1979.PubMedGoogle Scholar
  32. 32.
    Royal College of General Practitioners’ Oral Contraceptive Study. Further analysis of mortality in oral contraceptive users. Lancet 1:541, 1981.Google Scholar
  33. 33.
    Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: Findings of a large prospective study. Br Med J (Clin Res Ed) 292:526, 1986.Google Scholar
  34. 34.
    Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127, 1984.PubMedCrossRefGoogle Scholar
  35. 35.
    McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 303:435, 1991.PubMedGoogle Scholar
  36. 36.
    Kannel WB. Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study. Am Heart J 114:413, 1987.PubMedCrossRefGoogle Scholar
  37. 37.
    La Rosa JC. The varying effects of progestins on lipid levels and cardiovascular disease. Am J Obstet Gynecol 158:1621, 1988.PubMedGoogle Scholar
  38. 38.
    The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273:199, 1995.CrossRefGoogle Scholar
  39. 39.
    Kim CJ, Min YK. Apolipoprotein(a)-lowering effect of hormone replacement therapy in postmenopausal women may be one mechanism of cardioprotective effect of estrogen (abstr). J Am Coll Cardiol February (Special issue):431, 1994.Google Scholar
  40. 40.
    Kannel WB, D’Agostino RB, Belanger AJ. New insights on cholesterol-lipoprotein profiles: The Framingham Study. Presented at the 61st Scientific Sessions of the American Heart Association, November, 1988.Google Scholar
  41. 41.
    Freedman DS, Gruchow HW, Anderson AJ, Rimm AA, Barboriak JJ. Relation of triglyceride levels to coronary artery disease: The Milwaukee Cardiovascular Data Registry. Am J Epidemiol 127:1118, 1988.PubMedGoogle Scholar
  42. 42.
    Farmer JA, Gotto AM. Risk factors for coronary arcery disease. In Braunwald E (ed). Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders, 1992:1125.Google Scholar
  43. 43.
    Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 330:1062, 1994.PubMedCrossRefGoogle Scholar
  44. 44.
    Goebelsmann U, Maschak CA, Mishell DR. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 151:868, 1985.PubMedGoogle Scholar
  45. 45.
    Applebaum DM, Goldberg AP, Pykalisto OJ, Brunzell JD, Hazzard WR. Effect of estrogen on postheparin lipolytic activity. Selective decline in hepatic triglyceride lipase. J Clin Invest 59:601, 1977.PubMedGoogle Scholar
  46. 46.
    Wagner JD. Effect of estrogens on arterial LDL metabolism. Presented at the AHA Scientific Conference on Hormonal Metabolism and Cellular Influence on Cardiovascular Disease in Women, San Diego, CA, 1995.Google Scholar
  47. 47.
    Kovanen PT, Brown MS, Goldstein JL. Increased binding of low-density lipoprotein to liver membrane from rats treated with 17 alpha-ethinyl estradiol. J Biol Chem 254:1376, 1979.Google Scholar
  48. 48.
    Miller VT, La Rosa JC. Sex steroids and lipoproteins. In Redmond GP (ed). Lipids and Women’s Health. New York: Springer-Verlag, 1990:48.Google Scholar
  49. 49.
    Knopp RH. Cardiovascular effects of endogenous and exogenous sex hormones over a woman’s lifetime. Am J Obstet Gynecol 158:1630, 1988.PubMedGoogle Scholar
  50. 50.
    Runnebaum B, Rabe TR. New progestogens in oral contraceptives. Am J Obstet Gynecol 157:1059, 1987.PubMedGoogle Scholar
  51. 51.
    Harvengt C, Desager JP, Gaspard U, Lepot M. Changes in lipoprotein composition in women receiving two low-dose oral contraceptives containing ethinylestradiol and gonane progestins. Contraception 37:565, 1988.PubMedCrossRefGoogle Scholar
  52. 52.
    Kloosterboer HJ, van Wayjen RGA, van den Ende A. Comparative effects of monophasic desogesterel plus ethinyl estradiol and triphasic levonorgestrel plus ethinyloestradiol on lipid metabolism. Contraception 34:135, 1986.PubMedCrossRefGoogle Scholar
  53. 53.
    Gaspard UJ, Buret J, Gillain D, Romus MA, Lambotte R. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Contraception 31:395, 1985.PubMedCrossRefGoogle Scholar
  54. 54.
    März W, Gross W, Gahn G, Romberg G, Taubert HD, Kuhl H. A randomized crossover comparison of two low-dose contraceptives: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 153:287, 1985.PubMedGoogle Scholar
  55. 55.
    Ottosson UB, Johansson BG, Von Schoultz B. Subfractions of high density lipoprotein cholesterol during estrogen replacement: A comparison between progestogens and natural progesterone. Am J Obstet Gynecol 151:746, 1985.PubMedGoogle Scholar
  56. 56.
    Kim H-J, Kalkoff RK. Sex steroid influence on triglyceride metabolism. J Clin Invest 56:888, 1975.PubMedGoogle Scholar
  57. 57.
    Kim H-J, Kalkhoff RK. Changes in lipoprotein composition during the menstrual cycle. Metabolism 28:663, 1979.PubMedCrossRefGoogle Scholar
  58. 58.
    Basdevant A, De Lignieres B, Bigorie B, Guy-Grand B. Estradiol, progesterone, and plasma lipids during the menstrual cycle. Diabetes Metab 7:1, 1981.Google Scholar
  59. 59.
    Hemer HA, de Bourges VV, Ayala JJ, Brito G, Diaz-Sanchez V, and Garza-Flores J. Variations in serum lipase and lipoproteins throughout the menstrual cycle. Eur J Obstet Gynecol Reprod Biol 44:80, 1984.Google Scholar
  60. 60.
    Mattson L-A, Silfverstolpe G, Samsioe G. Lipid composition of serum lipoproteins in relation to gonadal hormone during the normal menstrual cycle. Eur J Obstet Gynecol Reprod Biol 17:327, 1984.CrossRefGoogle Scholar
  61. 61.
    Tikkanen MJ, Kuusi T, Nikkila EA, Stenman U-H. Variation of postheparin plasma hepatic lipase by menstrual cycle. Metabolism 35:99, 1986.PubMedCrossRefGoogle Scholar
  62. 62.
    Woods M, Schaefer EJ, Morrill A, Goldin BR, Longcope C, Dwyer JD, Gorbach SL. Effect of menstrual cycle phase on plasma lipids. J Clin Endocrinal Metab 65:321, 1987.Google Scholar
  63. 63.
    Herrera E, Lasuncion MA, Gomez-Coronado D, Aranda P, Lopez-Luna P, Maier I. Role of lipoprotein lipase activity on lipoprotein metabolism and the fate of circulating triglycerides in pregnancy. Am J Obstet Gynecol 158:1575, 1988.PubMedGoogle Scholar
  64. 64.
    Desoye G, Schweditsch M, Pfieffer KP, Zechner R, Kostner GH. Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. J Clin Endocrinol Metab 64:704, 1987.PubMedGoogle Scholar
  65. 65.
    Bengtsson B, Rybo G, Westerberg H. Number of pregnancies, use of oral contraceptives and menopausal age in women with ischaemic heart disease, compared to a population sample of women. Acta Med Scand 549(Suppl.):75, 1973.Google Scholar
  66. 66.
    Oliver ME. Ischaemic heart disease in young women. Br Med J 4:253, 1974.PubMedGoogle Scholar
  67. 67.
    Maschak CA, Lobo RA. Estrogen replacement therapy and hypertension. J Reprod Med 30:805, 1985.Google Scholar
  68. 68.
    Barrett-Connor E. Putative complications of estrogen replacement therapy: Hypertension, diabetes, thrombophlebitis, and gallstones. In Koernman SG (ed). The Menopause: Biological and Clinical Consequences of Ovarian Failure; Evolution and Management. Norwell, MA: Serono Symposia, 1990:199.Google Scholar
  69. 69.
    Lip GYH, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 8:491, 1994.PubMedGoogle Scholar
  70. 70.
    Woods JW. Oral contraceptives and hypertension. Hypertension 11(Suppl. II):11, 1988.Google Scholar
  71. 71.
    Wallace RB, Barrett-Connor E, Criqui M, Wahl P, Hoover J, Hunninghake D, Heiss G. Alteration in blood pressures associated with combined alcohol and oral contraceptive use — the lipid research clinics prevalence study. J Chronic Dis 35:251, 1982.PubMedCrossRefGoogle Scholar
  72. 72.
    Kaplan NM. Systemic hypertension: Mechanisms and diagnosis. In Braunwald E (ed). Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: W.B. Saunders, 1992:817.Google Scholar
  73. 73.
    Hassager C, Riis BJ, Strom V, Guyene TT, Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 76:753, 1987.PubMedGoogle Scholar
  74. 74.
    Kaplan NM(ed). Clinical Hypertension. Baltimore, MD: Williams and Wilkins, 1990:346.Google Scholar
  75. 75.
    McAreavey D, Cumming AM, Boddy K, Brown JJ, Praser R, Leckie BJ, Lever AF, Morton JJ, Robertson JI, Williams ED. The renin-angiotensin system and total body sodium and potassium in hypertensive women taking oestrogen-progestagen oral contraceptives. Clin Endocrinol Oxf 18:111, 1983.PubMedGoogle Scholar
  76. 76.
    Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959, 1993.PubMedGoogle Scholar
  77. 77.
    Kasdorf G, Kalkhoff RK. Prospective studies of insulin sensitivity in normal women receiving oral contraceptive agents. J Clin Endocrinol Metab 66:846, 1988.PubMedGoogle Scholar
  78. 78.
    Haarbo J, Leth-Espensen P, Stender S, Christiansen C. Estrogen monotherapy and combined estrogenprogestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 87:1274, 1991.PubMedGoogle Scholar
  79. 79.
    Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Arteriosclerosis 10:1051, 1990.PubMedGoogle Scholar
  80. 80.
    Wagner JD, Clarkson TB, St. Clair RW, Schwenke DC, Shively CA, Adams MR. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomologous monkeys. J Clin Invest 88:1995, 1991.PubMedGoogle Scholar
  81. 81.
    Jacobsson J, Cheng L, Lyke K, Kuwahara M, Kagan E, Ramwell PW, Foegh ML. Effect of estrodiol on accelerated atherosclerosis in rabbit heterotopic aortic allografts. J Heart Lung Transplant 11:1188, 1992.PubMedGoogle Scholar
  82. 82.
    Brown MS, Goldstein JL. Scavenging for receptors. Nature 343:508, 1990.PubMedCrossRefGoogle Scholar
  83. 83.
    Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91:2488, 1995.PubMedGoogle Scholar
  84. 84.
    Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87:5134, 1990.PubMedCrossRefGoogle Scholar
  85. 85.
    McEver RP. Leukocyte-endothelial interactions. Curr Opin Cell Biol 4:840, 1992.PubMedCrossRefGoogle Scholar
  86. 86.
    Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 89:1501, 1994.PubMedGoogle Scholar
  87. 87.
    Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 89:1943, 1994.PubMedGoogle Scholar
  88. 88.
    Fischer GM, Swain ML. Effect of sex hormones on blood pressure and vascular connective tissue is castrated and noncastrated male rats. Am J Physiol 232:H617, 1977.PubMedGoogle Scholar
  89. 89.
    Fischer GM, Cherian K, Swain ML. Inreased synthesis of aortic collagen and elastin in experimental atherosclerosis. Inhibition by contraceptive steroids. Atherosclerosis 39:463, 1981.PubMedCrossRefGoogle Scholar
  90. 90.
    Calgano D, Bei M, Ross SA, Klein A, Foegh ML. Effects of estrogen on vein grafts. J Cardiovasc Surg 33:579, 1992.Google Scholar
  91. 91.
    Demer LL. Estrogen and arterial wall calcification. Presented at the American Heart Association Scientific Conference on Hormonal Metabolism and Cellular Influence on Cardiovascular Disease in Women, San Diego CA, 1995.Google Scholar
  92. 92.
    Guetta V, Panza JA, Waclawiw MA, Cannon RO. Effect of combined 17-β estradiol and vitamin E on low-density lipoprotein oxidation in postmenopausal women. Am J Cardiol 75:1274, 1995.PubMedCrossRefGoogle Scholar
  93. 93.
    Mukai K, Daifuku K, Yokoyama S, Nakano M. Stopped-flow investigation of antioxidant activity of estrogens in solution. Biochim Biophys Acta 1035:348, 1990.PubMedGoogle Scholar
  94. 94.
    Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett 210:37, 1987.PubMedCrossRefGoogle Scholar
  95. 95.
    Huber LA, Scheffler E, Poll T, Ziegler R, Dresel HA. 17 beta-estradiol inhibits LDL oxidation and cholesteryl ester formation in cultured macrophages. Free Radic Res Commun 8:167, 1990.PubMedCrossRefGoogle Scholar
  96. 96.
    Rifici VA, Khachadurian AK. The inhibition of lowdensity lipoprotein oxidation by 17-β estradiol. Metabolism 41:1110, 1992.PubMedCrossRefGoogle Scholar
  97. 97.
    Subbiah MTR, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocinol Metab 77:1095, 1993.CrossRefGoogle Scholar
  98. 98.
    Keaney JF, Shwaery GT, Aiming X, Nicolosi RJ, Loscalo J, Foxall TL, Vita JA. 17-β estradiol preserves endothelial vasodilator function and limits low-densky lipoprotein oxidation in hypercholesterolemic swine. Circulation 89:2251, 1994.PubMedGoogle Scholar
  99. 99.
    Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 343:269, 1994.PubMedCrossRefGoogle Scholar
  100. 100.
    Sarrel PM. Effects of ovarian steroids on the cardiovascular system. In Ginsberg J (ed). Circulation in the Female. Park Ridge, NJ: Parthenon, 1989:117.Google Scholar
  101. 101.
    Sarrel PM, Lindsay D, Rosano GM, Poole-Wilson PA. Angina and normal coronary arteries in women: Gynecologic findings. Am J Obstet Gynecol 167:467, 1992.PubMedGoogle Scholar
  102. 102.
    Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 17-β estradiol on rabbit coronary artery contractile responses to endothelin-1. Heart Circ Physiol 263:H271, 1992.Google Scholar
  103. 103.
    Collins P, Rosano GMC, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA. Hypothesis: Cardiovascular protection by oestrogen: A calcium antagonist effect? Lancet 341:1264, 1993.PubMedCrossRefGoogle Scholar
  104. 104.
    Hayashi T, Fukoto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits: Implications for atherosclerosis. Proc Natl Acad Sci USA 89:11259, 1992.PubMedCrossRefGoogle Scholar
  105. 105.
    Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moneada S. Induction of calciumdependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 91:5212, 1994.PubMedCrossRefGoogle Scholar
  106. 106.
    Keaney JF, Shwaery GT, Xu A, Nicolosi RJ, Loscalzo J, Foxall TL, Vita JA. 17-β estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 89:2251, 1994.PubMedGoogle Scholar
  107. 107.
    Sudhir K, Chou TM, Mullen WL, Hausmann D, Collins P, Yock PG, Chattergee K. Mechanisms of estrogen-induced vasodilation. In vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol 26:807, 1995.PubMedCrossRefGoogle Scholar
  108. 108.
    Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium-independent relaxation of rabbit coronary artery to 17-β estradiol in vitro. Br J Pharmacol 104:1033, 1991.PubMedGoogle Scholar
  109. 109.
    Chang WC, Nakao J, Onmo H, Murota S. Stimulation of prostacyclin biosynthetic activity by estradiol in rat aortic smooth muscle cells in culture. Biochim Biophys Acta 619:107, 1980.PubMedGoogle Scholar
  110. 110.
    Magness RR, Rosenfeld CR. Local and systemic effects on uterine and systemic vasodilation. Am J Physiol 256:E536, 1989.PubMedGoogle Scholar
  111. 111.
    Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 20:452, 1992.PubMedCrossRefGoogle Scholar
  112. 112.
    Vanhoutte PM (ed). Vasodilation: Vascular Smooth Muscle, Peptides, Autonomic Nerves, and Endothelium. New York: Raven Press, 1988.Google Scholar
  113. 113.
    Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander W, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315:1046, 1986.PubMedCrossRefGoogle Scholar
  114. 114.
    Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89:2545, 1994.PubMedGoogle Scholar
  115. 115.
    Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 81:1680, 1990.PubMedGoogle Scholar
  116. 116.
    Gangar KF, Vyas S, Whitehead M, Crook D, Meire H, Campbell S. Pulsatility index in internal carotid artery in relation to transdermal oestrogen and time since menopause. Lancet 338:839, 1991.PubMedCrossRefGoogle Scholar
  117. 117.
    Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. Circulation 90:786, 1994.PubMedGoogle Scholar
  118. 118.
    Volterrani M, Rosano G, Coats A, Beale C, Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 99:119, 1994.CrossRefGoogle Scholar
  119. 119.
    Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endothelium-dependent, flowmediated vasodilation in postmenopausal women. Ann Intern Med 121:936, 1994.PubMedGoogle Scholar
  120. 120.
    Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 89:52, 1994.PubMedGoogle Scholar
  121. 121.
    Collins P, Rosano GMC, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA. 17-β estradiol attenuates acetylcholineinduced coronary arterial constriction in women but not men with coronary heart disease. Circulation 92:24, 1995.PubMedGoogle Scholar
  122. 122.
    Meade TW, Haines AP, Imeson JD, Stirling Y, Thompson SG. Menopausal status and haemostatic variables. Lancet I:22, 1983.CrossRefGoogle Scholar
  123. 123.
    Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: Sex differences and effects of the menopause. Br J Haematol 74:77, 1990.PubMedGoogle Scholar
  124. 124.
    Meilahn EN, Kuller LH, Matthews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 4:445, 1992.Google Scholar
  125. 125.
    Meade TW, Berra A. Hormone replacement therapy and cardiovascular disease. Br Med Bull 48:276, 1992.PubMedGoogle Scholar
  126. 126.
    Meilahn E, Kuller ME, Kiss LH, Matthews JR, Lewis KA. Coagulation parameters among preand post-menopausal women. Am J Epidemiol 28:908, 1990.Google Scholar
  127. 127.
    Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease — The Framingham Study. JAMA 258:1183, 1987.PubMedCrossRefGoogle Scholar
  128. 128.
    Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormonereplacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 328:1069, 1993.PubMedCrossRefGoogle Scholar
  129. 129.
    Saleh AA, Dorey LG, Dombrowski MP, Ginsburg KA, Hirokawa S, Kowalczyk C, Hirata J, Bottoms S, Cotton DB, Mammen EF. Thrombosis and hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 169:1554, 1993.PubMedGoogle Scholar
  130. 130.
    Layde PM, Beral V. Further analyses of mortality in oral contraceptive users: Royal College of General Practitioners’ Oral Contraception Study. Lancet 1:541, 1981.Google Scholar
  131. 131.
    Comp PC, Zacur HA. Contraceptive choices in women with coagulation disorders. Am J Obstet Gynecol 168:1990, 1993.PubMedGoogle Scholar
  132. 132.
    Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133:32, 1991.PubMedGoogle Scholar
  133. 133.
    Lobo RA. Estrogen and the risk of coagulopathy. Am J Med 92:283, 1992.PubMedCrossRefGoogle Scholar
  134. 134.
    Poller L, Thompson JM. Clotting factors during oral contraception: Further report. Br Med J 2:23, 1966.PubMedGoogle Scholar
  135. 135.
    Lee AJ, Lowe GDO, Smith WCS, Tunstall-Pedoe H. Plasma fibrinogen: Its relationship with oral contraception, the menopause and hormone replacement therapy. Clin Biochem 25:403, 1992.PubMedCrossRefGoogle Scholar
  136. 136.
    Petersen KR, Sidelmann J, Skouby SO, Jespersen J. Effects of monophasic low-dose oral contraceptives on fibrin formulation and resolution in young women. Am J Obstet Gynecol 168:32, 1993.PubMedGoogle Scholar
  137. 137.
    Mileikowsky GM, Nadler JL, Huey F, Francis R, Roy S. Evidence that smoking alters prostacyclin formation and platelet aggregation in women who use oral contraceptives. Am J Obstet Gynecol 159:1547, 1988.PubMedGoogle Scholar
  138. 138.
    Pan JQ, Hall ER, Wu KK. Alteration of platelet responses to metabolites of arachadonic acid by oral contraceptives. Br J Haematol 58:317, 1984.PubMedGoogle Scholar
  139. 139.
    Spina RJ, Ogawa T, Martin WH, Coggan AR, Holloszy JO, Ehsani AA. Exercise training prevents decline in stroke volume during exercise in young subjects. J Appl Physiol 72:2458, 1992.PubMedGoogle Scholar
  140. 140.
    Spina RJ, Ogawa T, Miller TR, Kohrt WM, Ehsani AA. Effect of exercise training on left ventricular performance in older women free of cardiopulmonary disease. Am J Cardiol 71:99, 1993.PubMedCrossRefGoogle Scholar
  141. 141.
    Spina RJ, Ogawa T, Kohrt WM, Martin WH, Holloszy JO, Ehsani AA. Differences in cardiovascular adaptations to endurance exercise training between older men and women. J Appl Physiol 75:849, 1993.PubMedGoogle Scholar
  142. 142.
    Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in woman with coronary disease. Lancet 342:133, 1993.PubMedCrossRefGoogle Scholar
  143. 143.
    Mandel FP, Geola FL, Meldrum DR, Lu JH, Eggena P, Sambhi MP, Hershman JM, Judd HL. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 57:133, 1983.PubMedGoogle Scholar
  144. 144.
    Lobo RA, March CM, Goebelsmann U, Krauss RM, Mishell DR Jr. Subdermal estradiol pellets following hysterectomy and oophorectomy. Effect upon serum estrone, estradiol, luteinizing hormone, folliclestimulating hormone, corticosteroid binding globulin-binding capacity, testosterone-estradiol binding globulin-binding capacity, lipids, and hot flushes. Am J Obstet Gynecol 138:714, 1980.PubMedGoogle Scholar
  145. 145.
    Farish E, Fletcher CD, Hart R, et al. The effects of hormone implants on serum lipoproteins and steroid hormones in bilaterally oopherectomized women. Acta Endocrinol (Copenhagen) 106:116, 1984.Google Scholar
  146. 146.
    Sharf M, Oettinger M, Lanir A, Kahana L, Yeshurun D. Lipid and lipoprotein levels following pure estradiol implantation in post-menopausal women. Gynecol Obstet Invest 19:207, 1985.PubMedCrossRefGoogle Scholar
  147. 147.
    Jensen J, Riis BJ, Strom V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 156:66, 1987.PubMedGoogle Scholar
  148. 148.
    Fahraeus L, Larsson-Cohn U, Wallentin L. Lipoproteins during oral and cutaneous administration of estradiol-17 beta to menopausal women. Acta Endocrinol 101:597, 1982.PubMedGoogle Scholar
  149. 149.
    Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK. Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL. Biological effects of transdermal estradiol. N Engl J Med 314:1615, 1986.PubMedCrossRefGoogle Scholar
  150. 150.
    Lipson A, Stoy DB, LaRosa JC, et al. Progestins and oral contraceptive-induced lipoprotein changes: A prospective study. Contraception 34:121, 1986.PubMedCrossRefGoogle Scholar
  151. 151.
    Powell MC, Hedlin AM, Cerkus I, et al. Effects of oral contraceptives on lipoprotein lipids: A prospective study. Obstet Gynecol 63:764, 1966.Google Scholar
  152. 152.
    Burkman RT, Robinson JC, Kruszon-Moran D, Kimball AW, Kwiterovich P, Burford RG. Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. Obstet Gynecol 71:33, 1988.PubMedGoogle Scholar
  153. 153.
    Krauss RM, Roy S, Mishell DR Jr, et al. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: Different changes in high-density lipoprotein subclasses. Am J Obstet Gynecol 145:446, 1983.PubMedGoogle Scholar
  154. 154.
    Percival-Smith RK, Morrison BJ, Sizto R, Abercrombie B. The effects of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women. Contraception 35:179, 1987.PubMedCrossRefGoogle Scholar
  155. 155.
    Knopp RH. Arteriosclerotic risk. The roles of oral contraceptives and postmenopausal estrogens. J Reprod Med 31:913, 1986.PubMedGoogle Scholar
  156. 156.
    Knopp RH. Metabolic adjustments in normal and diabetic pregnancy. Clin Obstet Gynecol 24:21, 1981.PubMedCrossRefGoogle Scholar
  157. 157.
    Kaplan NM. Clinical Hypertension, 5th ed. Baltimore, MD: Williams and Wilkins, 1990:346.Google Scholar
  158. 158.
    Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6:67, 1989.PubMedCrossRefGoogle Scholar
  159. 159.
    Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 342:133, 1993.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Linda R. Peterson

There are no affiliations available

Personalised recommendations